David E Fry

US Patent:

20040067942, Apr 8, 2004

Filed:

Aug 1, 2003

Appl. No.:

10/632281

Inventors:

William Elliott - Ann Arbor MI, US
David Fry - Ypsilanti MI, US

International Classification:

A61K031/7072
A61K031/5377
A61K031/337

US Classification:

514/234200, 514/050000, 514/449000

Abstract:

Administration of an irreversible tyrosine kinase inhibitor such as CI-1033 in combination with one or more other antineoplastic agent(s), or ionizing radiation is synergistic for treating cancer.

US Patent:

20050222163, Oct 6, 2005

Filed:

Mar 30, 2005

Appl. No.:

11/095442

Inventors:

Stephen Eck - Ann Arbor MI, US
David Fry - Ypsilanti MI, US
Judith Leopold - Ann Arbor MI, US

International Classification:

A61K031/519

US Classification:

514252160

Abstract:

The present invention relates to methods for treating cancer comprising utilizing a combination of signal transduction inhibitors. More specifically, the present invention relates to combinations of so called cell cycle inhibitors with mitogen stimulated kinase signal transduction inhibitors, more specifically combinations of CDK inhibitors with mitogen stimulated kinase signal transduction inhibitors, more preferably MEK inhibitors. Other embodiments of the invention relate to additional combinations of the aforesaid combinations with standard anti-cancer agents such as cytotoxic agents, palliatives and antiangiogenics. Most specifically this invention relates to combinations of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one including salt forms, which is a selective cyclin-dependent kinase 4 (CDK4) inhibitor, in combination with one or more MEK inhibitors, most preferably N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide. The aforementioned combinations are useful for treating inflammation and cell proliferative diseases such as cancer and restenosis.

US Patent:

20060293323, Dec 28, 2006

Filed:

Aug 14, 2006

Appl. No.:

11/464249

Inventors:

William Elliott - Ann Arbor MI, US
David Fry - Ypsilanti MI, US

International Classification:

A61K 31/5377
A61K 31/7072
A61K 31/7048
A61K 31/704
A61K 31/337
A61K 31/282
A61K 31/4745

US Classification:

514234200, 424649000, 514027000, 514034000, 514049000, 514449000, 514492000, 514283000

Abstract:

Administration of an irreversible tyrosine kinase inhibitor such as CI-1033 in combination with one or more other antineoplastic agent(s), or ionizing radiation is synergistic for treating cancer.

US Patent:

20120185174, Jul 19, 2012

Filed:

Jan 17, 2012

Appl. No.:

13/351485

Inventors:

William P. Worzel - Milan MI, US
Peter F. Lenehan - Chelsea MI, US
Arpit Almal - Gujurat, IN
David W. Fry - Ypsilanti MI, US

Assignee:

Everist Genomics, Inc. - Ann Arbor MI

International Classification:

G06F 19/10
C40B 40/06
C07H 21/04

US Classification:

702 19, 536 243, 506 16

Abstract:

An assay system is useful for predicting recurrence and/or non-recurrence of colorectal cancer in a patient. The assay system is adapted to analyze a patient sample for quantitative expression of a prognostic genetic profile correlated with colorectal cancer recurrence. The profile includes the expression of the nucleic acid sequences of SEQ ID NOS: 1, 2, 3, 4, and 5.

US Patent:

57212660, Feb 24, 1998

Filed:

Sep 26, 1994

Appl. No.:

8/312253

Inventors:

Stuart James Decker - Ann Arbor MI
David William Fry - Ypsilanti MI
James Marino Hamby - Ann Arbor MI
Alan Robert Saltiel - Ann Arbor MI

Assignee:

Warner-Lambert Company - Morris Plains NJ

International Classification:

A01N 4350

US Classification:

514398

Abstract:

Methods of treating proliferative diseases or viral, inflammatory, allergic and cardiovascular diseases, and restenosis are disclosed. The present invention demonstrates the use of N,N'-piperazinylbis-�2-amino-1-imidazolin-2-yl)-2-imidazolines!, 2-amino-1-(2-imidazolin-2-yl)-2-imidazolines, and N,N'-alkylene-bis�2-amino-1-(2-imidazolin-2-yl)-2-imidazolines!, their derivatives, and salts thereof, to antagonize the association of a protein tyrosine kinase with a substrate regulatory protein. The present invention also demonstrates the use of pharmaceutical compositions employing N,N'-piperazinylbis�2-amino-1-imidazolin-2-yl)-2-imidazolines!, 2-amino-1-(2-imidazolin-2-yl)-2-imidazolines, and N,N'-alkylenebis-�2-amino-1-(2-imidazolin-2-yl)-2-imidazolines!, their derivatives, and salts thereof, to antagonize the association of a protein tyrosine kinase with substrate regulatory protein. The present invention also relates to novel N,N'-piperazinylbis�2-amino-1-imidazolin-2-yl)-2-imidazolines!.

US Patent:

D314150, Jun 6, 1989

Filed:

May 7, 1986

Appl. No.:

6/859895

Inventors:

David F. Fry - Birmingham MI
Louis J. Crosslen - Saukville WI
John L. Kraus - Shorewood WI

Assignee:

Chrysler Motors Corporation - Highland Park MI

US Classification:

D 6432